Slate Medicines Launches With $130M Series A
2026-02-24
Tweet
RALEIGH, NC, Slate Medicines, a privately-held biotech company advancing next-generation therapeutics for headache disorders, today announced the close of a $130 million Series A round.
Slate Medicines today announced the close of a $130 million Series A financing, alongside the in-licensing of SLTE-1009, an anti-PACAP monoclonal antibody licensed from DartsBio Pharmaceuticals (Guangdong), Ltd.
Financing was co-led by RA Capital Management, Forbion, and Foresite Capital with participation from an additional undisclosed biotech investor.
Slate Medicines is a biotech company focused on advancing next generation therapeutics for migraine and other headache disorders. The Company's lead program, SLTE-1009, is a potential best-in-class subcutaneous anti-PACAP for the prevention of migraine and other headache disorders.
Financing was co-led by RA Capital Management, Forbion, and Foresite Capital with participation from an additional undisclosed biotech investor.
Slate Medicines is a biotech company focused on advancing next generation therapeutics for migraine and other headache disorders. The Company's lead program, SLTE-1009, is a potential best-in-class subcutaneous anti-PACAP for the prevention of migraine and other headache disorders.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
